Immediate discontinuation if severe hypersensitivity or anaphylactic-type reactions occur. Shock could develop if accidentally administered into a blood vessel. Monitor for any symptoms throughout infusion period. Risk of adverse reactions is more frequent when receiving human normal Ig for the 1st time or, in rare cases, when switching between human normal Ig products or when there has been long interval since the previous infusion. Patients w/ anti-IgA Ab should be treated under close medical supervision. Patients at risk for thrombosis should receive Cuvitru at the slowest infusion rate practicable; monitor for thrombotic complications. Aseptic Meningitis Syndrome may occur, more frequently in female patients. Monitor for hemolysis, particularly those at increased risk. Interference w/ serological testing (eg, misleading or false positive results). Possible transmission of infectious agents. May impair ability to drive or operate machinery. Renal impairment. Pregnancy & lactation. Childn <2 yr.